Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.760
-0.200 (-6.76%)
At close: Apr 15, 2026, 4:00 PM EDT
2.850
+0.090 (3.26%)
After-hours: Apr 15, 2026, 4:45 PM EDT
Ovid Therapeutics Employees
Ovid Therapeutics had 23 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
23
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$315,304
Profits / Employee
-$745,304
Market Cap
363.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 23 | 0 | - |
| Dec 31, 2024 | 23 | -17 | -42.50% |
| Sep 30, 2024 | 25 | -14 | -35.90% |
| Jun 30, 2024 | 40 | 0 | - |
| Mar 31, 2024 | 40 | -6 | -13.04% |
| Dec 31, 2023 | 40 | -4 | -9.09% |
| Sep 30, 2023 | 39 | -5 | -11.36% |
| Jun 30, 2023 | 40 | -4 | -9.09% |
| Mar 31, 2023 | 46 | -3 | -6.12% |
| Dec 31, 2022 | 44 | -13 | -22.81% |
| Sep 30, 2022 | 44 | -1 | -2.22% |
| Jun 30, 2022 | 44 | -16 | -26.67% |
| Mar 31, 2022 | 49 | -15 | -23.44% |
| Dec 31, 2021 | 57 | -10 | -14.93% |
| Sep 30, 2021 | 45 | -20 | -30.77% |
| Jun 30, 2021 | 60 | 0 | - |
| Mar 31, 2021 | 64 | -1 | -1.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Rocket Pharmaceuticals | 202 |
| Puma Biotechnology | 179 |
| Nautilus Biotechnology | 130 |
| Niagen Bioscience | 117 |
| Lineage Cell Therapeutics | 77 |
| Candel Therapeutics | 55 |
| X4 Pharmaceuticals | 45 |
OVID News
- 7 days ago - Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 - GlobeNewsWire
- 4 weeks ago - Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally - Benzinga
- 4 weeks ago - Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Ovid Therapeutics Announces Pricing of $60 Million Private Placement - GlobeNewsWire
- 7 weeks ago - Ovid Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) - GlobeNewsWire
- 4 months ago - Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer - GlobeNewsWire
- 5 months ago - Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire